Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III crossover study of RSVPreF3 maternal vaccine versus Boostrix in healthy non-pregnant girls and women
2021-004003-41Phase 3Terminated
- Sponsor
- GSK
- Start
- Nov 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of GSK3003899A in respiratory syncytial virus disease (RSV) (2 arms), sponsored by GSK. Primary endpoint: RSV A neutralizing antibody titers at pre-dosing. Started Nov 2021; status: terminated.
02
Drugs
GSK3003899A
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2021-004003-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004003-41.